Contrave, approved in 2014, combines naltrexone and bupropion through a different mechanism than newer agents like Mounjaro, which activates both GLP-1 and GIP receptors to produce stronger metabolic effects
2,97 The EFSA also states that B12 has not been found to be carcinogenic or mutagenic in in vitro and in vivo studies
Arai, M., Imai, H., Koumura, T., Yoshida, M., Emoto, K., Umeda, M., Chiba, N., and Nakagawa, Y
However, if PLP levels exceed 200 nmol/L or if you develop numbness or tingling in the extremities, discuss with your provider about potential B6 accumulation
We offer a consistent program regardless of dosage changes, ensuring you dont face unexpected cost increases as your treatment progresses